A progressive pathological animal model for drug evaluation and a method for constructing the same
By constructing a progressive pathological animal model through a sequential three-stage synergistic induction method, the problem of inaccurate simulation of the T2DM-CRS course in existing technologies has been solved, achieving a high model success rate, low individual variability, and low mortality rate, thereby improving the accuracy and reliability of drug evaluation.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGDONG LAIDI BIOMEDICAL RES INST CO LTD
- Filing Date
- 2026-04-22
- Publication Date
- 2026-07-21
AI Technical Summary
The existing technology lacks animal models that can accurately simulate the progressive natural course of type 2 diabetes mellitus complicated with cardiorenal syndrome (T2DM-CRS) in humans. The modeling rate is low, individual differences are large, mortality is high, the course of the disease is uncontrollable, and the fit with clinical practice is low, resulting in poor consistency between preclinical evaluation results and clinical trial results during drug development.
A sequential three-stage synergistic induction method was adopted to gradually induce insulin resistance, subclinical cardiorenal damage, and progressive fibrosis in rats by feeding them with a high-fat, high-fructose, and high-cholesterol diet, injecting them with low-dose streptozotocin, and intermittently injecting them with angiotensin II, thus constructing a progressive pathological animal model.
It enables controllable and precise staging of the disease course, reduces individual differences and mortality, improves the model success rate, and the model characteristics are highly consistent with clinical practice, thereby enhancing the accuracy and reliability of drug evaluation and reducing the risk of drug development failure.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3